- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: 2C I.
Displaying page 1 of 1.
EudraCT Number: 2021-001329-29 | Sponsor Protocol Number: TIG-006 | Start Date*: 2021-07-15 |
Sponsor Name:iTeos Belgium SA | ||
Full Title: A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors | ||
Medical condition: Advanced solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) IT (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000283-62 | Sponsor Protocol Number: KB103-001 | Start Date*: 2023-03-21 | |||||||||||
Sponsor Name:Krystal Biotech | |||||||||||||
Full Title: A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | |||||||||||||
Medical condition: Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002026-20 | Sponsor Protocol Number: CT7001-001 | Start Date*: 2017-10-31 |
Sponsor Name:Carrick Therapeutics | ||
Full Title: A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malign... | ||
Medical condition: Module 1A: All solid malignancies Module 1B: Solid malignancies, potentially including TNBC, SCLC, CRPC, ovarian cancer patients, and other appropriate cancer indications. Module 1B-1 (TNBC):... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2009-012591-27 | Sponsor Protocol Number: VAC037 | Start Date*: 2009-11-16 |
Sponsor Name:University of Oxford | ||
Full Title: A phase I/IIa study to assess the safety and immunogenicity of new malaria vaccine candidates AdCh63 MSP1 alone and with MVA MSP1 | ||
Medical condition: Plasmodium Falciparum Malaria | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003018-17 | Sponsor Protocol Number: SPD489-322 | Start Date*: 2012-10-10 |
Sponsor Name:Shire Development LLC | ||
Full Title: The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002173-28 | Sponsor Protocol Number: C4391002 | Start Date*: 2023-01-25 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMB... | ||||||||||||||||||
Medical condition: HR-positive HER2-negative metastatic/advanced BC | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Ongoing) CZ (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002279-16 | Sponsor Protocol Number: EOGBM1-18 | Start Date*: 2020-01-02 | |||||||||||
Sponsor Name:Enterome | |||||||||||||
Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe... | |||||||||||||
Medical condition: Progressive or recurrent Glioblastoma (PG) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000122-21 | Sponsor Protocol Number: NVL-655-01 | Start Date*: 2022-07-27 |
Sponsor Name:Nuvalent, Inc. | ||
Full Title: A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) | ||
Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors with ALK rearrangement or activating ALK mutation. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005546-38 | Sponsor Protocol Number: AEZS-108-050 | Start Date*: 2013-10-14 | ||||||||||||||||
Sponsor Name:Aeterna Zentaris GmbH | ||||||||||||||||||
Full Title: Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer | ||||||||||||||||||
Medical condition: Endometrial cancer, advanced, recurrent or metastatic | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: CZ (Completed) BE (Completed) GB (Completed) AT (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) BG (Completed) NL (Completed) PL (Completed) DK (Completed) FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014431-20 | Sponsor Protocol Number: REGENERA | Start Date*: 2010-02-12 |
Sponsor Name:Andrés Íñiguez Romo | ||
Full Title: Contribución de la administración precoz de GH a la regeneración y remodelado favorable del miocardio ventricular izquierdo en pacientes con infarto agudo de miocardio | ||
Medical condition: Reducción del volumen miocárdico necrótico en pacientes con infarto agudo de miocardio tratados mediante angioplastia transluminal | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004104-34 | Sponsor Protocol Number: SNDX-5613-0700 | Start Date*: 2022-04-20 | |||||||||||
Sponsor Name:Syndax Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nu... | |||||||||||||
Medical condition: Relapsed or Refractory Acute Leukemias | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) LT (Ongoing) DE (Temporarily Halted) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002251-42 | Sponsor Protocol Number: 3-001 | Start Date*: 2012-11-05 | |||||||||||
Sponsor Name: Asahi Kasei Pharma America Corporation | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, PLACEBO–CONTROLLED, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY | |||||||||||||
Medical condition: severe sepsis and coagulopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) HU (Completed) FI (Completed) CZ (Completed) ES (Completed) BG (Prematurely Ended) GB (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023986-23 | Sponsor Protocol Number: LF-0802 | Start Date*: 2011-05-27 | |||||||||||
Sponsor Name:Agennix Incorporated | |||||||||||||
Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003561-16 | Sponsor Protocol Number: TAK-242/01-04-TL-242-011 | Start Date*: 2005-12-21 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis | |||||||||||||
Medical condition: Severe sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002400-40 | Sponsor Protocol Number: CTTG01-01 | Start Date*: 2012-11-09 | |||||||||||
Sponsor Name:Targovax AS | |||||||||||||
Full Title: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas | |||||||||||||
Medical condition: Adenocarcinoma of the Pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) GB (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003006-25 | Sponsor Protocol Number: SPD489-323 | Start Date*: 2012-02-02 |
Sponsor Name:Shire Development Inc. | ||
Full Title: The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressan... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) CZ (Completed) BE (Completed) EE (Completed) FI (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-000192-14 | Sponsor Protocol Number: TMC-CAN-05-02 | Start Date*: 2006-12-21 | |||||||||||
Sponsor Name:The Medicines Company | |||||||||||||
Full Title: A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects Who Require Percutaneous Coronary Intervention | |||||||||||||
Medical condition: Subjects with coronary atherosclerosis who require PCI (with or without stent). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000071-25 | Sponsor Protocol Number: JE049-3101 | Start Date*: 2009-09-10 | |||||||||||
Sponsor Name:Jerini AG | |||||||||||||
Full Title: Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of He... | |||||||||||||
Medical condition: hereditary angioedema, HAE (in adult patients with C1-esterase-inhibitor deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003935-56 | Sponsor Protocol Number: TMC-CAN-05-03 | Start Date*: 2006-11-24 | |||||||||||
Sponsor Name:The Medicines Company | |||||||||||||
Full Title: A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention | |||||||||||||
Medical condition: Subjects with coronary atherosclerosis (excluding ST segment-elevation MI [STEMI]) who require PCI (with or without stent). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) CZ (Prematurely Ended) LT (Completed) SK (Completed) DE (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.